title: Does Treatment of Ocular Myasthenia Gravis With Early Immunosuppressive Therapy Prevent Secondarily Generalization and Should It Be Offered to All Such Patients?
authors.affiliation: Department of Neuro-ophthalmology (SHW, GTP), Moorfields Eye Hospital, London, United Kingdom; Medical Eye Unit (SHW, GTP), St. Thomas' Hospital, London, United Kingdom; Department of Neuro-ophthalmology (SHW, GTP), National Hospital for Neurology and Neurosurgery, London, United Kingdom; and Departments of Neurology and Ophthalmology (WC), University of Michigan, Ann Arbor, Michigan.
authors.forename: Sui H
authors.initials: SH
authors.lastname: Wong
authors.forename: Gordon T
authors.initials: GT
authors.lastname: Plant
authors.forename: Wayne
authors.initials: W
authors.lastname: Cornblath
mesh_terms: D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000517:prevention & control; D055502:Secondary Prevention
chemical_list: D007166:Immunosuppressive Agents